Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Employees - 45, CEO - Brian Lian, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): 73.26, Piotroski Score(max is 10): 1, Working Capital: $712636000, Total Assets: $739415000, Retained Earnings: $-689884000, EBIT: -274842000, Total Liabilities: $26385000, Revenue: $0

AryaFin Target Price - $0.23 - Current Price $ - Analyst Target Price $